Clinical trialNCT05714839RecruitingPhase 1/PHASE2Interventional

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

SponsorGlaxoSmithKlineEnrollment123Multiple Myeloma

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

GSK Clinical Trials
GlaxoSmithKline
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

36 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Argentina

Gsk Investigational Site
Ciudadela, Argentina
Completed
Gsk Investigational Site
Rosario, Argentina
Herman Perroud
Recruiting
Gsk Investigational Site
San Juan Bautista, Argentina
Maria Julieta Dalmaroni
Recruiting
Gsk Investigational Site
Viedma, Argentina
Rubén Kowalyszyn
Recruiting

Australia

Gsk Investigational Site
Fitzroy, Victoria, Australia
Hang Quach
Recruiting
Gsk Investigational Site
Nedlands, Western Australia, Australia
Completed

Brazil

Gsk Investigational Site
Joinville, Brazil
Marcelo Pitombeira de Lacerda
Recruiting
Gsk Investigational Site
Salvador, Brazil
Edvan de Queiroz Crusoe
Recruiting
Gsk Investigational Site
São Paulo, Brazil
Vania Hungria
Recruiting

Israel

Gsk Investigational Site
Jerusalem, Israel
moshe gatt
Recruiting

Japan

Gsk Investigational Site
Aomori, Japan
Tomoaki Akagi
Recruiting
Gsk Investigational Site
Chiba, Japan
Junichiro Yuda
Recruiting
Gsk Investigational Site
Kanagawa, Japan
Tomonori Nakazato
Recruiting
Gsk Investigational Site
Osaka, Japan
Completed
Gsk Investigational Site
Tokyo, Japan
Kazuhito Suzuki
Recruiting
Gsk Investigational Site
Yamagata, Japan
satoshi ito
Recruiting

Poland

Gsk Investigational Site
Gdansk, Poland
Withdrawn
Gsk Investigational Site
Lublin, Poland
Marek Hus
Recruiting

South Korea

Gsk Investigational Site
Seoul, South Korea
chang-ki min
Recruiting
Gsk Investigational Site
Seoul, South Korea
Dok Hyun Yoon
Recruiting

Taiwan

Gsk Investigational Site
Changhua, Taiwan
Hsuan-Yu Lin
Recruiting
Gsk Investigational Site
Kaohsiung City, Taiwan
Shih-Feng Cho
Recruiting
Gsk Investigational Site
Taipei, Taiwan
SHANG YI Huang
Recruiting

Turkey (Türkiye)

Gsk Investigational Site
Istanbul, Turkey (Türkiye)
SINEM BOZDAG
Recruiting
Gsk Investigational Site
Kayseri, Turkey (Türkiye)
Neslihan Mandaci sanli
Recruiting

United Kingdom

Gsk Investigational Site
Leicester, United Kingdom
Linda Barton
Recruiting
Gsk Investigational Site
Oxford, United Kingdom
Completed
Gsk Investigational Site
Plymouth, United Kingdom
Hannah Hunter
Recruiting

United States

Gsk Investigational Site
Bullhead City, Arizona, United States
Hamdy Mohtaseb
Recruiting
Gsk Investigational Site
Pembroke Pines, Florida, United States
Isaac Levy
Recruiting
Gsk Investigational Site
Grand Rapids, Michigan, United States
Andrew Sochacki
Recruiting
Gsk Investigational Site
Chapel Hill, North Carolina, United States
Eben Lichtman
Recruiting
Gsk Investigational Site
Wilson, North Carolina, United States
Keith Lerro
Recruiting
Gsk Investigational Site
Canton, Ohio, United States
Nashat Gabrail
Recruiting
Gsk Investigational Site
Chattanooga, Tennessee, United States
Jesus Berdeja →
Recruiting
Gsk Investigational Site
Nashville, Tennessee, United States
Jesus Berdeja →
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 14 Jun 2023
Primary completion: 3 Aug 2028
Completion: 3 Aug 2028
Last update posted: 10 Jul 2026
Registered enrollment: 123
Registry id: NCT05714839

Cross-registrations

EU-CTR / CTIS (EudraCT)2022-501941-63-00

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.